Modified dynamic risk stratification for predicting recurrence using the response to initial therapy in patients with differentiated thyroid carcinoma.

OBJECTIVE A new risk stratification system was proposed to estimate the risk of recurrence in patients with differentiated thyroid carcinoma (DTC) using the response to initial therapy. Here, we describe the modified dynamic risk stratification system, which takes into consideration the status of serum anti-Tg antibody (TgAb), and validate this system for assessing the risk of recurrence in patients with DTC. PATIENTS AND METHODS Patients who underwent total thyroidectomy with radioiodine remnant ablation due to DTC between 2000 and 2005 were included. We classified patients into four groups based on the response to the initial therapy ('excellent', 'acceptable', 'biochemical incomplete', and 'structural incomplete' response). RESULTS The median follow-up period of 715 patients with DTC was 8 years. The response to initial therapy was an important risk predictor for recurrent/persistent DTC. The relative risks (95% CI) of recurrence were 16.5 (6.3-43.0) in the 'acceptable response' group, 41.3 (15.4-110.8) in the 'biochemical incomplete response' group, and 281.2 (112.9-700.5) in the 'structural incomplete response' group compared with the 'excellent response' group (P<0.001, P<0.001, and P<0.001 respectively). The disease-free survival rate of the 'excellent response' group to initial therapy was 98.3% whereas that of the 'structural incomplete response' group was only 6.8%. CONCLUSIONS Our study validates the usefulness of the modified dynamic risk stratification system including the status of serum TgAb for predicting recurrent/persistent disease in patients with DTC. Personalized risk assessment using the response to initial therapy could be useful for the follow-up and management of patients with DTC.

[1]  Y. Youn,et al.  Changes in the clinicopathological characteristics and outcomes of thyroid cancer in Korea over the past four decades. , 2013, Thyroid : official journal of the American Thyroid Association.

[2]  R. Stanković,et al.  Influence of Initial Treatment on the Survival and Recurrence in Patients With Differentiated Thyroid Microcarcinoma , 2013, Clinical nuclear medicine.

[3]  T. Pellegrino,et al.  Should patients with remnants from thyroid microcarcinoma really not be treated with iodine-131 ablation? , 2013, Endocrine.

[4]  N. Sakamoto,et al.  Population-based study evaluating and predicting the probability of death resulting from thyroid cancer and other causes among patients with thyroid cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  S. Mandel,et al.  The prognostic significance of nodal metastases from papillary thyroid carcinoma can be stratified based on the size and number of metastatic lymph nodes, as well as the presence of extranodal extension. , 2012, Thyroid : official journal of the American Thyroid Association.

[6]  Tae Yong Kim,et al.  Long-term clinical outcome of differentiated thyroid cancer patients with undetectable stimulated thyroglobulin level one year after initial treatment. , 2012, Thyroid : official journal of the American Thyroid Association.

[7]  R. Tuttle,et al.  Spontaneous remission in thyroid cancer patients after biochemical incomplete response to initial therapy , 2012, Clinical endocrinology.

[8]  T. Montesano,et al.  Long-term surveillance of papillary thyroid cancer patients who do not undergo postoperative radioiodine remnant ablation: is there a role for serum thyroglobulin measurement? , 2012, The Journal of clinical endocrinology and metabolism.

[9]  R. Tuttle,et al.  In differentiated thyroid cancer, an incomplete structural response to therapy is associated with significantly worse clinical outcomes than only an incomplete thyroglobulin response. , 2011, Thyroid : official journal of the American Thyroid Association.

[10]  C. Spencer Clinical review: Clinical utility of thyroglobulin antibody (TgAb) measurements for patients with differentiated thyroid cancers (DTC). , 2011, The Journal of clinical endocrinology and metabolism.

[11]  G. Cevenini,et al.  Delayed risk stratification, to include the response to initial treatment (surgery and radioiodine ablation), has better outcome predictivity in differentiated thyroid cancer patients. , 2011, European journal of endocrinology.

[12]  Tae Yong Kim,et al.  The outcomes of first reoperation for locoregionally recurrent/persistent papillary thyroid carcinoma in patients who initially underwent total thyroidectomy and remnant ablation. , 2011, The Journal of clinical endocrinology and metabolism.

[13]  J. Shah,et al.  Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. , 2010, Thyroid : official journal of the American Thyroid Association.

[14]  Stephanie L. Lee,et al.  Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. , 2009, Thyroid : official journal of the American Thyroid Association.

[15]  T. Sebo,et al.  Papillary thyroid microcarcinoma: a study of 900 cases observed in a 60-year period. , 2008, Surgery.

[16]  Tae Yong Kim,et al.  Change of serum antithyroglobulin antibody levels is useful for prediction of clinical recurrence in thyroglobulin-negative patients with differentiated thyroid carcinoma. , 2008, The Journal of clinical endocrinology and metabolism.

[17]  B. Lang,et al.  Staging Systems for Papillary Thyroid Carcinoma: A Review and Comparison , 2007, Annals of surgery.

[18]  A. Bockisch,et al.  Development and clinical impact of thyroglobulin antibodies in patients with differentiated thyroid carcinoma during the first 3 years after thyroidectomy. , 2005, European journal of endocrinology.

[19]  C. Spencer Challenges of serum thyroglobulin (Tg) measurement in the presence of Tg autoantibodies. , 2004, The Journal of clinical endocrinology and metabolism.

[20]  Stephanie L. Lee,et al.  A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. , 2003, The Journal of clinical endocrinology and metabolism.

[21]  B. Cady Presidential address: beyond risk groups--a new look at differentiated thyroid cancer. , 1998, Surgery.

[22]  B. O'Sullivan,et al.  A comparison of different staging systems predictability of patient outcome , 1997, Cancer.

[23]  M. Schemper,et al.  The relative importance of prognostic factors in studies of survival. , 1991, Statistics in medicine.

[24]  E. Kaplan,et al.  Natural history, treatment, and course of papillary thyroid carcinoma. , 1990, The Journal of clinical endocrinology and metabolism.

[25]  B. Cady,et al.  An expanded view of risk-group definition in differentiated thyroid carcinoma. , 1988, Surgery.

[26]  J. Romijn,et al.  Survival and death causes in differentiated thyroid carcinoma. , 2006, The Journal of clinical endocrinology and metabolism.

[27]  F. Greene,et al.  AJCC cancer staging handbook : from the AJCC cancer staging manual , 2002 .

[28]  L. Davies,et al.  Increasing incidence of thyroid cancer in the United States, 1973-2002. , 2006, JAMA.